Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis

References

• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–778. doi:10.1016/S0140-6736(07)60363-817336654
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.14760812
   PubMed Web of Science ®Google Scholar
• Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches. Clin Epidemiol. 2014;6:379–393. doi:10.2147/CLEP.S5316825368531
   PubMed Web of Science ®Google Scholar
• Manners PJ, Diepeveen DA. Prevalence of juvenile chronic arthritis in a population of 12-year-old children in urban Australia. Pediatrics. 1996;98:84–90.8668417
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar Nivedita M, Saag KG, et al. American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;2011(63):465–482. doi:10.1002/acr.20460
   Web of Science ®Google Scholar
• Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65:2499–2512. doi:10.1002/art.3809224092554
   PubMed Web of Science ®Google Scholar
• Dueckers G, Guellac N, Arbogast M, et al. Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol. 2012;142:176–193. doi:10.1016/j.clim.2011.10.00322154868
   PubMed Web of Science ®Google Scholar
• McMahan R, Balfe LM, Greene L. Summary of AHRQ’s comparative effectiveness review of disease-modifying antirheumatic drugs for children with juvenile idiopathic arthritis. J Manag Care Pharm. 2012;18:1–16. doi:10.18553/jmcp.2012.18.S1-B.1
   PubMedGoogle Scholar
• Kemper A, Coeytaux R, Sanders GD, et al. AHRQ Comparative Effectiveness Reviews. Disease-Modifying Antirheumatic Drugs (DMARDS) in Children with Juvenile Idiopathic Arthritis (JIA). Rockville, MD: Agency for Healthcare Research and Quality (US); 2011.
   Google Scholar
• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–2149. doi:10.1016/S0140-6736(11)60244-421684384
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol. 2015;67:2759–2770. doi:10.1002/art.3923426097215
   PubMed Web of Science ®Google Scholar
• Truckenbrodt H, Häfner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 1986;29:801–807.3718568
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child. 2003;88:197–200. doi:10.1136/adc.88.3.19712598376
   PubMed Web of Science ®Google Scholar
• Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004;22:271–275.15144118
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Listing J, Biedermann T, Schöntube M, Zink A. Burden and cost of illness in patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:836–842. doi:10.1136/ard.2003.00851615194580
   PubMed Web of Science ®Google Scholar
• Moorthy LN, Peterson MGE, Hassett AL, Lehman TJA. Burden of childhood-onset arthritis. Pediatr Rheumatol Online J. 2010;8:20. doi:10.1186/1546-0096-8-2020615240
   PubMedGoogle Scholar
• Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19:952–955.1404133
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Listing J, et al. The economic burden of juvenile idiopathic arthritis-results from the german paediatric rheumatologic database. Clin Exp Rheumatol. 2009;27:863–869.19917175
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57:44–48. doi:10.1002/art.2246317266088
   PubMedGoogle Scholar
• Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51:1407–1415. doi:10.1093/rheumatology/kes01922447885
   PubMed Web of Science ®Google Scholar
• Gidman W, Meacock R, Symmons D. The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication. Curr Rheumatol Rep. 2015;17:31. doi:10.1007/s11926-015-0508-125874347
   PubMed Web of Science ®Google Scholar
• United States Department of Labor, Bureau of Labor Statistics. Consumer Price index detailed report: annual average of 2017 tables. Available from: https://www.bls.gov/cpi/tables/home.htm. Accessed 222, 2018.
   Google Scholar
• Kabir MH, Laila K, Haque M, Rahman SA. Drug compliance in children with juvenile idiopathic arthritis and reasons for poor compliance. Am JClin Exp Med. 2017;5:15–18. doi:10.11648/j.ajcem.20170501.14
   Google Scholar
• Pelajo CF, Sgarlat CM, Lopez-Benitez JM, et al. Adherence to methotrexate in juvenile idiopathic arthritis. Rheumatol Int. 2012;32:497–500. doi:10.1007/s00296-010-1774-x21246362
   PubMedGoogle Scholar
• Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum. 2009;38:396–402. doi:10.1016/j.semarthrit.2008.01.01118336875
   PubMed Web of Science ®Google Scholar
• Kuhlmann A, Schmidt T, Treskova M, et al. Social/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe. Eur J Health Econ. 2016;17(Suppl 1):79–87. doi:10.1007/s10198-016-0786-127086322
   PubMed Web of Science ®Google Scholar
• Poddighe D, Romano M, Gattinara M, Gerloni V. Biologics for the treatment of juvenile idiopathic arthritis. Curr Med Chem. 2018;25(42):5860–5893. doi:10.2174/092986732566618052208571629788871
   PubMedGoogle Scholar
• Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–828. doi:10.1136/annrheumdis-2018-21303029643108
   PubMed Web of Science ®Google Scholar